Background and objectives Inhibition of the renin-angiotensin-aldosterone system decreases proteinuria and slows estimated GFR decline in patients with type 2 diabetes mellitus with overt nephropathy. Serum aldosterone levels may increase during renin-angiotensin-aldosterone system blockade. The determinants and consequences of this aldosterone breakthrough remain unknown.
Introduction
Inhibition of the renin-angiotensin-aldosterone system (RAAS), either through angiotensin-converting enzyme inhibitors (ACEIs) in patients with diabetes type 1 (1) and nondiabetics (2, 3) or angiotensin II receptor blockers (ARBs) in patients with type 2 diabetes mellitus (T2DM) (4, 5) , decreases proteinuria and slows down the decline in GFR in patients with proteinuria. Indeed, residual proteinuria is a predictor of progression to renal failure (6) . However, despite RAAS blockade, many patients display high residual proteinuria levels and develop ESRD (7) . It is possible that RAAS blockade strategies may be suboptimal, because serum aldosterone levels may increase during RAAS blockade with all ACEIs (8) or ARBs (9) tested so far. The incidence of this aldosterone breakthrough is up to 53% after 1 year of RAAS blockade, depending on the definition used (10) . Aldosterone breakthrough is usually defined by the increase in serum aldosterone levels compared with baseline levels before RAAS blockade and ranges from 40% to 53% at 1 year (10). Aldosterone breakthrough seems to be independent of the RAAS blocker dosage (11) and does not differ with ACEI or ARB treatment (12) .
Aldosterone breakthrough may be associated with cardiovascular and renal morbidity. Indeed, it may reverse the beneficial effects of an ACEI on left ventricular hypertrophy (13) , and the improvement in functional capacity noted in patients with congestive heart failure treated with ACEI is decreased when aldosterone breakthrough is present (14) . High serum aldosterone levels are an independent risk factor for in-hospital cardiovascular/renal morbidity or mortality after myocardial infarction (15) . In patients with diabetic or IgA nephropathies, aldosterone breakthrough is associated with higher levels of proteinuria levels (8, 12) , and progression to renal failure may be more rapid in diabetic patients with aldosterone breakthrough (9) . Furthermore, serum aldosterone has been reported to induce inflammation and fibrosis in experimental animals (16) and therefore, could accelerate renal damage.
The aim of this posthoc analysis was to establish the incidence, determinants, and changes associated with aldosterone breakthrough after ARB treatment in participants included in the AMADEO study (losArtan versus telMisArtan in hypertensive type-2 DiabEtic patients with Overt nephropathy) (17) .
Materials and Methods

Study Design and Patient Population
A total of 860 participants with T2DM with first morning spot urinary albumin creatinine ratio (UACR)$700 mg/g was included in AMADEO, a prospective, randomized, double-blind, controlled, multicenter, parallel-group trial that compared the effects of losartan versus telmisartan on the UACR after 1 year of treatment (17) . Serum aldosterone levels were measured at inclusion, 6 months, and study end (1 year). In this posthoc analysis, we excluded patients with missing serum aldosterone measurements, because either they did not complete the 1-year trial because of events or one serum aldosterone value was missing during follow-up.
After a 4-week placebo washout period, with discontinuation of any ARB, ACEI, or direct vasodilator therapy, eligible participants were randomized to one time daily losartan or telmisartan. During the first 2 weeks, the dose was 50 mg for losartan and 40 mg for telmisartan. For the remaining 50 weeks, the doses of losartan and telmisartan were 100 and 80 mg, respectively. Additional antihypertensive medication (excluding other ARBs, ACEIs, or aldosterone inhibitors) could be administered after forced titration to achieve BP targets (,130/80 mmHg).
Data for the Posthoc Analyses
Data on age, sex, body mass index, seated trough systolic BP (SBP) and diastolic BP (DBP), UACR, urinary sodium creatinine ratio (UNaCR), glycosylated hemoglobin (HbA1c), estimated GFR (eGFR) with simplified Modification of Diet in Renal Disease formula, and additional antihypertensive treatments were available at baseline, 6 months, and 1 year. The 24-hour urinary sodium excretion, a good marker of daily sodium intake, was extrapolated from UNaCR in morning urine spots as previously shown using Mann's formula (18) .
Blood was collected between 7:00 and 10:00 a.m. after the patient had rested in the seated position for 30 minutes to determine serum aldosterone levels at baseline, 6 months, and 1 year. Centrifugation was performed within 30 minutes, and 1-ml plasma aliquots were stored at 280°C. Serum aldosterone levels were measured with a commercially available radioimmunoassay kit (ALDO-RIACT; Schering AG, Berlin, Germany). The normal serum aldosterone range was considered to be 42-201 pg/ml.
Three groups of aldosterone level changes were defined: (1) participants with a true aldosterone breakthrough (defined as an increase of serum aldosterone levels greater than 10% over baseline values to take into account the upper limit of the within-and between-subject coefficients of variation of the assay) (19, 20) , (2) participants with the expected decrease of serum aldosterone levels greater than 10% below baseline values, and (3) participants with nonclinically significant fluctuation of serum aldosterone levels.
To assess whether aldosterone breakthrough predicted changes in eGFR and albuminuria between 6 months and 1 year, we looked at aldosterone breakthrough at 6 months and analyzed subsequent changes in renal function from 6 months to 1 year.
Statistical Analyses
Normally distributed variables were expressed as means 6 SD, and other variables were log-transformed to obtain normal distribution and reported as geometric mean 3/4 SD. Changes of log-transformed quantitative values over time were expressed as geometric mean percent 3/4 SD (21). Normally distributed variables were compared by one-way ANOVA. Qualitative values were compared using the chi-squared test.
To study the determinants of aldosterone breakthrough, we first analyzed baseline variables associated with baseline serum aldosterone levels by univariate and multivariate regression analyses. Second, we searched for the baseline and follow-up variables associated with aldosterone breakthrough at 1 year as a binary variable (comparing participants with significant increase or decrease of serum aldosterone levels) or a continuous variable (absolute variation of serum aldosterone between baseline and 1 year) by univariate regression analyses. All the relevant clinical and biologic variables and additional antihypertensive treatments were then included in a multivariate logistic regression analysis with nested models. The first model (M1) included baseline variables, whereas the second model (M2) included both M1 and changes observed in these variables from baseline to 1 year to estimate the adjusted odds ratios and 95% confidence interval for aldosterone breakthrough at 1 year.
Because our definition of aldosterone breakthrough excluded patients with nonsignificant serum aldosterone changes from the statistical analysis, the results were confirmed in the total study population by an analysis of serum aldosterone levels as a continuous variable using a general regression model.
Because Na intake is a strong determinant of serum aldosterone production, additional analyses were performed in participants with increased or decreased sodium intake from baseline to 1 year. After testing for interactions between characteristics and aldosterone breakthrough in the two subgroups of patients with increased or decreased Na intake during follow-up, we performed a multivariate analysis with all the significant interactions in the total study population.
Because of the colinearity between SBP and DBP, only SBP was included in the multivariate analyses, because it was found to have a more statistically significant association with aldosterone breakthrough in univariate analysis.
To address the possibility of regression to the mean, we considered different statistical adjustments for baseline as well as average serum aldosterone levels during follow-up as previously described (22) .
Analyses were performed using SAS software v9.1 (SAS institute, Cary, NC). All P values were two-tailed, and P values,0.05 were considered statistically significant. because they had completed the 1-year study and had morning serum aldosterone values available at baseline, 6 months, and 1 year. The baseline characteristics of the included and excluded participants are reported in Table 1 ; 173 participants did not complete the trial (death, renal replacement therapy, or lost to follow-up), and 121 participants had missing values of serum aldosterone during follow-up, including 14 patients with missing values at 6 months.
The statistically significant differences between participants who were included in the posthoc analysis and participants who were excluded were ethnicity, UACR, and eGFR. Indeed, excluded participants were more frequently black and less frequently Asian, and they had higher UACRs and lower eGFRs (Table 1) . Baseline serum aldosterone levels were independently and negatively correlated with eGFR, UACR, sodium intake, and serum potassium levels (Supplemental Table 1 ).
Incidence and Determinants of Aldosterone Breakthrough at 1 Year
Serum aldosterone levels increased in 40% of participants, but only 28% of participants exhibited a true aldosterone breakthrough at 1 year as defined by an increase of serum aldosterone levels greater than 10% over baseline values. After 1 year of ARB treatment, mean changes from baseline were 2213/492.5% for serum aldosterone levels, 22.3619.2 mmHg for SBP, 22.2611.1 mmHg for DBP, 2243/4137% for UACR, +5.53/4117% for UNaCR, +0.1061.4% for HbA1c, and 27.369.7 ml/min per 1.73 m 2 for eGFR in the overall posthoc analysis population.
Univariate analysis showed that factors associated with aldosterone breakthrough at 1 year included higher baseline SBP and UACR and lower baseline serum aldosterone levels ( Table 2 ). The changes in clinical and biologic parameters during follow-up that were significantly associated with aldosterone breakthrough were a greater decrease in SBP, sodium intake, and eGFR and a greater increase of serum potassium from baseline to 1 year (Table 2) .
In multivariate analysis, the baseline characteristics independently associated with aldosterone breakthrough at 1 year were higher SBP, lower serum aldosterone, and lower serum potassium levels after adjustment (for age, sex, ethnicity, smoking status, baseline HbA1c, UNaCR, UACR, eGFR, and antihypertensive treatment) ( Table 3) . After additional adjustment for changes in HbA1c, UACR, UNaCR, serum potassium levels, and additional antihypertensive treatment taken during follow-up (Table 3) , the baseline characteristics and follow-up parameters that were statistically significantly associated with aldosterone breakthrough at 1 year were lower serum aldosterone and potassium levels at baseline, higher decreases in SBP, sodium intake, and eGFR from baseline to 1 year, and use of losartan versus telmisartan. When the variation of serum aldosterone levels was analyzed as a continuous variable, statistically significant associations were found with low baseline serum aldosterone and potassium levels, significant decreases in SBP, sodium intake, and eGFR, and significant increases in serum potassium levels and ARB treatment ( Table 4 ). The same results were found with adjustment for average serum aldosterone levels during follow-up instead of baseline serum aldosterone levels.
Sensitivity Analysis in Participants Who Decreased Versus
Increased Their Sodium Intake during the Study Aldosterone breakthrough occurred in 93 of 272 participants (34%) who had a decrease of sodium intake and only 65 of 295 participants (22%) who had an increase of sodium intake from baseline to 1 year. The magnitude of Na intake changes during follow-up was the only variable that showed a statistically significant interaction with aldosterone breakthrough in the two subgroups of patients with increased or decreased Na intake during follow-up. The magnitude of Na intake decrease during follow-up (but not Na intake increase) was significantly associated with aldosterone breakthrough (Table 5 ). The determinants independently associated with aldosterone breakthrough, including this significant interaction with changes of sodium intake during follow-up, were unchanged, except for baseline serum potassium (Table 5 ). Multivariate analyses in the two subgroups of patients with increased or decreased Na intake during follow-up are shown in Supplemental Table 2 , A and B.
Changes in Study Parameters between 6 Months and 1 Year Associated with Aldosterone Breakthrough at 6 Months
Aldosterone breakthrough was observed in 163 participants at 6 months, and 112 of these participants (69%) did not present aldosterone breakthrough at 1 year. Multivariate analysis showed that aldosterone breakthrough at 
6 months did not predict eGFR decrease and proteinuria increase between 6 months and 1 year (Table 6 ).
Discussion
Our study provides the largest-scale confirmation so far that aldosterone breakthrough is a frequent event 1 year after initiating RAAS blockade, and it is the first study to provide data suggestive of potential mechanisms behind aldosterone breakthrough.
At baseline, serum aldosterone levels were higher in participants with lower sodium intake and serum potassium levels. Although the diuretic dosage was not reported during the study, lower serum potassium levels suggest higher doses of thiazide or loop diuretics, which may, together with lower sodium intake, stimulate aldosterone synthesis. Indeed, a lower serum potassium level would feed back to decrease serum aldosterone levels in the absence of hypovolemia (23) . Sodium depletion may also be the link between high serum aldosterone levels and low UACR and eGFR at baseline, which was previously shown (24) (25) (26) . Inversely, subsequent aldosterone breakthrough was more frequent if the patient had, at baseline, the opposite profile suggestive of hypervolemia (i.e., lower serum aldosterone levels and higher SBP in multivariate analysis as well as higher UACR in univariate analysis). Serum potassium levels were forced in the multivariate model, despite the absence of association with aldosterone breakthrough in univariate analysis, because of the known physiologic relationship between serum potassium and aldosterone levels. Indeed, high serum potassium levels should favor an increase of aldosterone secretion. However, the respective roles of potassium and diuretic treatments on aldosterone breakthrough remain uncertain, because neither the diuretic dosage nor potassium intake and urine potassium was reported during the study. The multivariate analysis with follow-up variables showed that aldosterone breakthrough was associated with a greater decrease in sodium intake, SBP, and eGFR over the study period. This result suggests that intensive BP-and proteinuria-lowering strategies with sodium restriction may be a triggering factor for the development of aldosterone breakthrough, which may then counteract part of the beneficial effects of low BP in the long term. When we analyzed the subgroup of participants with a decrease of sodium intake from baseline to 1 year, the main determinant of aldosterone breakthrough was, indeed, a lower sodium intake. Furthermore, in the subgroup of participants who increased their sodium intake during the study, the main determinants of aldosterone breakthrough were lower SBP and eGFR, suggesting again a direct effect of hemodynamic changes.
Serum potassium levels increased during the study after the introduction of ARB and with the decrease of eGFR during follow-up. Higher serum potassium levels should favor an increase of serum aldosterone levels by a physiologic feedback loop. Indeed, the observed increase of serum potassium was statistically significantly associated with an increased risk of aldosterone breakthrough.
Losartan exposed participants to a higher risk of aldosterone breakthrough than telmisartan, an effect that was independent of all the other covariables. Indeed, 57% of subjects with aldosterone breakthrough were taking losartan. Aldosterone secretion is subject to nycthemeral variations, with higher levels during the night that may be further increased by volume depletion during the day using loop diuretics (23). Short-acting RAAS blockers, such as losartan, may not effectively block the peak nocturnal RAAS activity when administered in the morning and therefore, could favor aldosterone breakthrough. This finding might explain why short-acting RAAS blockers may be more efficient in lowering ambulatory BP when administered in the evening (27, 28) . However, long-acting ARB is not the only and definitive answer to prevent aldosterone breakthrough. Indeed, 43% of subjects with aldosterone breakthrough were taking telmisartan.
We did not observe a faster eGFR decrease between 6 months and 1 year in participants with aldosterone breakthrough at 6 months. In fact, the aldosterone breakthrough status is not definitive at 6 months in this intervention study with ongoing forced titration to achieve BP targets,130/80 mmHg. Long-term study would be required to assess the consequence of sustained aldosterone breakthrough.
The major strength of this study is the well characterized population of participants with T2DM with overt nephropathy who were followed in a prospective, randomized, double-blind, double-dummy, forced titration, multicenter, parallel-group study; this study has the largest number of participants reported so far with centralized measurement of serum aldosterone levels and extensive data collection, including additional antihypertensive treatments, UNaCR, UACR, and serum potassium levels, to adjust for potential confounding factors. However, our posthoc analysis has several limitations. First, it excluded participants with a missing serum aldosterone measurement because of incomplete follow-up during the first year, mostly because of events but also because of missing values. The baseline characteristics of participants excluded because of incomplete serum aldosterone values differed regarding ethnicity, with fewer black participants, as well as higher UACR and lower eGFR (Table 1) . Second, regression to the mean may be mentioned, because lower baseline serum aldosterone levels were associated with subsequent higher incidence of aldosterone breakthrough. However, the appropriate statistical adjustments for baseline as well as average serum aldosterone levels were performed as previously described (22) . Serum aldosterone levels were measured at baseline, 6 months, and study end at 1 year. However, we may miss potential day-to-day variations, which may only be partially addressed by the definition of aldosterone breakthrough as a 10% increase over baseline values to take into account the upper limit of the withinand between-subject coefficients of variation of the assay previously reported in the literature. Indeed, these coefficients of variation are fairly high (19) . Furthermore, we did not measure urine aldosterone and renin. Third, sodium intake was not assessed but indirectly evaluated with Mann's formula from spot UNaCR values as previously shown (18) . Fourth, diuretic dosages were not reported during the study. However, a diuretic effect may be extrapolated from serum potassium levels, because only thiazide and loop diuretics were allowed during the study, although we did not measure urine potassium and potassium intake. Fifth, no information on whether the ARB was taken in the morning or the evening is available. Because the time of drug intake was not predefined in this study, some participants may have taken the short-acting ARB (losartan) in the evening, thereby decreasing the power of the comparison between the two ARBs if the hypothesis of the need for blocking nighttime RAAS overactivity to reduce aldosterone breakthrough is accepted. Finally, the 1-year study duration did not allow the long-term detrimental consequences of aldosterone breakthrough to be thoroughly investigated.
It can be concluded that aldosterone breakthrough is a frequent event in participants with T2DM with overt nephropathy after the initiation of ARB treatment, and it may be favored by baseline hypervolemia, subsequent greater decrease in SBP, sodium intake, and eGFR during follow-up, and use of a short-acting ARB. Long-term studies are required to test whether prevention of aldosterone breakthrough by cautious dual ACEI/ARB blockade in specific patient populations (29, 30) or aldosterone inhibitors (31) would lead to improved nephroprotection. 
